U.S. Markets
Johnson & Johnson (JNJ) to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology; will be USD 2.2bln upfront and USD 1.125bln in milestone payments
ORIGINAL · NewsquawkJohnson & Johnson (JNJ) to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology; will be USD 2.2bln upfront and USD 1.125bln in milestone paymentsRead originalHide original
Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema.
StockNow breaking-news AI analysis
J&J is acquiring Ollin Biosciences, adding Phase 3 candidate OLN324; Reuters had reported prior discussions of $2.2 billion upfront and $1.2 billion in potential milestones.
News detail
Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
